An antiproton is the antimatter counterpart of the proton. It has the same mass and spin as a regular proton but carries a negative electric charge instead of a positive one. If an antiproton meets a proton, the two annihilate each other and convert their combined mass into energy, mostly in the form of short-lived particles called pions. Antiprotons are rare in nature, but physicists produce and study them in particle accelerators to answer some of the deepest questions about why the universe is made of matter rather than antimatter.
How Antiprotons Compare to Protons
The simplest way to think of an antiproton is as a mirror image of a proton. Its mass is identical: about 938 million electron volts (a unit physicists use for subatomic masses), exactly the same as a proton. Its spin, a quantum property that describes how it behaves in a magnetic field, is also the same. The only differences are flipped signs: where a proton has a positive electric charge, the antiproton’s charge is negative, and its magnetic moment (the tiny magnetic field it generates) points in the opposite direction.
These mirror-image properties aren’t a coincidence. They’re a requirement of one of the most fundamental rules in physics, called CPT symmetry. This rule says that if you simultaneously flip a particle’s charge, mirror its spatial orientation, and reverse the flow of time, the laws of physics should look exactly the same. High-precision measurements at CERN have confirmed this: the ratio of the antiproton’s magnetic moment to the proton’s is negative one to within about five parts per ten billion. As far as anyone can measure, the symmetry is perfect.
Discovery at the Bevatron
The antiproton was first observed on September 21, 1955, at the University of California’s Radiation Laboratory in Berkeley. Physicists Owen Chamberlain, Emilio Segrè, Clyde Wiegand, and Thomas Ypsilantis used the Bevatron, then the most powerful particle accelerator in the world, capable of accelerating protons to energies of about 6.5 billion electron volts. That was just enough energy to create new proton-antiproton pairs when fast-moving protons slammed into a target. The team identified the antiprotons by carefully measuring the momentum and velocity of the particles that emerged. Their discovery, published in Physical Review Letters on November 1, 1955, earned Chamberlain and Segrè the 1959 Nobel Prize in Physics.
How Antiprotons Are Created
Making an antiproton requires converting raw energy into matter, following Einstein’s famous relationship between energy and mass. In practice, this means smashing high-energy protons into a dense target. When enough energy is concentrated in the collision, the surplus can materialize as new particle-antiparticle pairs, including a proton and an antiproton. The minimum energy needed for this reaction is about 5,630 million electron volts, which corresponds to six times the mass-energy of a single proton.
At higher energies, well above 150 billion electron volts, antiproton production becomes more efficient because secondary collisions within the target material also contribute. Today, CERN’s facilities generate antiprotons by firing a beam of protons into a metal target, then magnetically separating the antiprotons from the spray of other particles.
What Happens When Antiprotons Meet Matter
When an antiproton collides with a proton, both particles are destroyed in a process called annihilation. Their combined mass converts entirely into energy, producing a burst of particles, primarily pions. These pions carry away the energy and quickly decay into lighter particles like muons and neutrinos. The total energy released from a single proton-antiproton annihilation is roughly 1,876 million electron volts, an enormous amount for a subatomic event. For perspective, that’s nearly 2,000 times the energy a proton carries just from its own mass.
This annihilation is what makes antimatter both fascinating and impractical as an energy source. Gram for gram, matter-antimatter annihilation releases more energy than any other known process, but producing and storing antiprotons requires far more energy than you’d ever get back.
Antiprotons in Nature
You don’t need a particle accelerator to find antiprotons. They exist naturally, though in tiny quantities. Cosmic rays, the high-energy particles that rain down on Earth from deep space, occasionally strike atoms in interstellar gas and produce antiprotons through the same kind of nuclear reactions physicists use in the lab. These “galactic” antiprotons are secondary products, born when cosmic ray protons crash into interstellar matter during their long journeys through the galaxy’s magnetic fields.
The same process happens closer to home. When cosmic rays hit atoms in Earth’s upper atmosphere at altitudes around 1,000 kilometers, they can produce antiprotons that become trapped by the planet’s magnetic field, forming a thin antiproton radiation belt. Models predict that the antiproton fluxes in this belt are roughly a hundred times greater than the interstellar fluxes at comparable energies, because Earth’s magnetic field accumulates and confines the particles. Cosmic ray helium nuclei contribute about 25% of this antiproton production.
How Scientists Store Antiprotons
Since antiprotons annihilate instantly on contact with ordinary matter, keeping them around for study is a significant engineering challenge. The solution is a device called a Penning trap, which uses a combination of electric and magnetic fields to suspend charged particles in a vacuum, never letting them touch the walls. The antiprotons float in this electromagnetic cage, completely isolated from normal matter.
The technique has become remarkably refined. In the longest demonstration to date, a team at CERN’s BASE experiment kept a cloud of antiprotons continuously trapped and monitored for 614 days, more than a year and a half. That record represents the longest uninterrupted confinement of antimatter ever achieved in a laboratory.
What Antiproton Research Is Trying to Answer
CERN operates two specialized facilities for antiproton research: the Antiproton Decelerator (AD) and the Extra Low Energy Antiproton ring (ELENA). Together, they slow antiprotons down to very low speeds so multiple experiments can study them with extreme precision.
The central question driving this work is whether antimatter truly obeys the same laws as matter in every measurable way. Some experiments compare the fundamental properties of protons and antiprotons, looking for any tiny deviation that would break CPT symmetry and point toward physics beyond our current theories. Others combine antiprotons with positrons (anti-electrons) to create antihydrogen, the simplest anti-atom, and then test whether it responds to gravity the same way ordinary hydrogen does. If antimatter fell upward, or even fell slightly differently than matter, it would upend our understanding of gravity and potentially help explain why the observable universe contains so much more matter than antimatter.
Additional experiments use antiprotons as probes to study the surfaces of atomic nuclei, measuring the “neutron skin,” the thin outer layer of neutrons on certain exotic nuclei, with a sensitivity that other methods can’t match.
Potential Medical Applications
One intriguing line of research has explored whether antiprotons could be used in cancer treatment. Proton therapy already works by firing beams of protons into tumors. Protons deposit most of their energy at a specific depth in tissue, sparing healthy tissue in front of and behind the tumor. Antiprotons would do the same, but with a bonus: when they stop inside the tumor and annihilate with atoms in the tissue, they release a burst of additional energy right at the target.
The first direct measurements of this effect, carried out by the AD-4/ACE experiment at CERN, confirmed that antiprotons deliver a biological dose comparable to protons along most of their path through tissue but show a steep increase in effectiveness at the point where they stop and annihilate. This means the extra damage is concentrated precisely where you’d want it, inside the tumor, while the entrance path through healthy tissue sees only a modest increase. These results represent early proof-of-concept work rather than a ready-to-use therapy, since producing enough antiprotons for clinical use remains far beyond current capabilities.